The Food and Drug Administration Oct. 13 issued and immediately implemented enforcement policy for modifications to FDA-cleared molecular influenza and RSV tests during the COVID-19 public health emergency to expand access to certain FDA-cleared molecular tests for detecting and identifying flu viruses and respiratory syncytial viruses.

The agency notes that these tests often require the same critical components as many SARS-CoV-2 molecular assays.

Related News Articles

Headline
As COVID-19 surges continue, lessons learned by health systems large and small reveal the importance of teamwork, communication, flexibility, preparation and…
Headline
The Centers for Disease Control and Prevention today reported 10 cases of anaphylaxis, a life-threatening allergic reaction, among the more than 4 million…
Headline
Full-dose blood thinner treatments can reduce the need for vital organ support such as ventilation in moderately ill patients hospitalized for COVID-19,…
Perspective
“We have much to do, much to repair, much to restore, much to heal, much to build … and much to gain.” President Biden focused on healing and unity in his…
Headline
AHA today released its latest issue of the COVID-19 Snapshot, which underscores the dire needs of hospitals and health systems during the deepening public…
#HealthCareInnovation Thursday Blog
If you’re like me and have been tracking the media over the past several months, then you have seen dozens of examples of rural health care leaders…